This study identifies PHF2 as an important downstream effector of AMPK that inhibits lung cancer metastasis, highlighting PHF2-S655 phosphorylation as the potential biomarker in lung cancer metastasis and promoting the clinical application of metformin into suppressing tumorigenesis and development. The gene discussed is PRKAA1; the disease is lung carcinoma.